Stefan Aebi, MD
The survival benefit with adjuvant chemotherapy in ER-negative breast cancer patients with isolated locoregional recurrence (ILRR) was sustained in the final analysis of the phase III CALOR trial. Patients in the study with ER-positive disease did not derive a similar survival benefit.
The improvement in DFS associated with chemotherapy remained significant in a multivariable proportional hazards model that included factors for ER status of ILRR, location of ILRR, previous chemotherapy use, and interval from primary surgery. The interaction between ER status and chemotherapy effect was statistically significant, confirming the efficacy of chemotherapy depending on ER expression of the ILRR. The multivariable analysis of BCFI gave similar results, again with a statistically significant interaction between ER status and efficacy of chemotherapy.
Wapnir IL, Price KN, Anderson SJ, et al. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial [published online February 14, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.76.5719.
... to read the full story